Ticker

Analyst Price Targets — CNSP

Page 1 • Showing up to 10
DateAnalystFirmTargetPrice @ PostSourceHeadline
September 10, 2024 7:40 amJason McCarthyMaxim Group$0.50$0.15StreetInsider Maxim Group Upgrades CNS Pharmasceuticals Inc. (CNSP) to Buy, 'Berubicin Glioblastoma Data is Coming into View'

Latest News for CNSP

CNS Pharmaceuticals Details Business Development Strategy Driving Its Next Phase of Growth

Chief Business Officer, Dylan Wenke, Participates in Virtual Investor "What This Means" Segment Access the segment here HOUSTON, TX / ACCESS Newswire / September 1, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today announced that it participated in a Virtual Investor…

Accesswire • Sep 1, 2026
CNS Pharmaceuticals Participates in the Virtual Investor "Why Now" On-Demand Conference

Video webcast now available here HOUSTON, TX / ACCESS Newswire / August 27, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today announced that it participated in the Virtual Investor "Why Now" on-demand conference. Rami Levin, President and Chief Executive Officer of…

Accesswire • Aug 27, 2026
CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation

Company reports approximately $20.0 million cash position and extended operating runway following oversubscribed $22.5 million financing, as it advances its pivot toward a diversified, high-value pipeline HOUSTON, TX / ACCESS Newswire / August 12, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing…

Accesswire • Aug 12, 2026
CNS Pharmaceuticals CFO, Steve O'Loughlin, Highlights Company's Recent $22.5M Financing in Virtual Investor "What This Means" Segment

Access the segment here HOUSTON, TX / ACCESS Newswire / June 8, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today announced that it participated in a Virtual Investor "What This Means" Segment. Steve O'Loughlin, Chief Financial Officer of CNS Pharmaceuticals,…

Accesswire • Jun 8, 2026

🧮 Earnings Move Analyzer

Insider Trading

Insider Trading

NameRoleDateTypeSharesPriceFormLink

No Senate trades found for CNSP.

No House trades found for CNSP.

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top